natgillin/translations-raw huggingface dataset:
If you stop taking Ziagen If you have stopped taking Ziagen for any reason, particularly because you think you are having side effects or for other illness, it is important that you contact your doctor before restarting.
Če ste prenehali jemati zdravilo Ziagen Če ste zaradi kateregakoli razloga prenehali jemati zdravilo Ziagen, še zlasti zato ker mislite, da imate neželene učinke ali kakšno drugo bolezen, je pomembno, da se pred ponovnim začetkom jemanja posvetujete s svojim zdravnikom.
In some cases your doctor will ask you to restart Ziagen in a place where you will be able to get ready access to medical care if needed.
V nekaterih primerih vas bo zdravnik prosil, da s ponovnim jemanjem zdravila Ziagen začnete na kraju, kjer vam bo po potrebi takoj dostopna zdravniška pomoč.
Like all medicines, Ziagen can cause side effects, although not everybody gets them.
Kot vsa zdravila ima lahko tudi zdravilo Ziagen neželene učinke, ki pa se ne pojavijo pri vseh bolnikih.
When treating HIV infection, it is not always possible to tell whether some of the undesirable effects that occur are caused by Ziagen, by other medicines you are taking at the same time or by the HIV disease.
Pri zdravljenju okužb s HIV ni vedno mogoče vedeti, ali neželene učinke, ki se pojavijo, povzroča zdravilo Ziagen, kakšno drugo zdravilo, ki ga sočasno jemljete, ali pa bolezen sama.
For this reason it is very important that you inform your doctor about any changes in your health.
Zaradi tega je nadvse pomembno, da svojega zdravnika obvestite prav o vsaki spremembi svojega zdravstvenega stanja.
A hypersensitivity reaction (serious allergic reaction) has been reported in about 5 in every 100 patients who have been treated with Ziagen.
O preobčutljivostni reakciji (resni alergični reakciji) so poročali pri približno petih od stotih bolnikov, ki so se zdravili z zdravilom Ziagen.
This is described under “ Take special care with Ziagen ” in section 2 of this leaflet.
To je opisano pod naslovom "Bodite posebno pozorni pri uporabi zdravila Ziagen" v poglavju 2 tega navodila.
It is important that you read and understand the information about this serious reaction.
Pomembno je, da informacije o tej resni reakciji preberete in pravilno razumete.
Common side effects (reported in 1 to 10 out of 100 patients):
Pogosti neželeni učinki (pri 1 do 10 od 100 bolnikov):
- skin rash (without any other illness)
- kožni izpuščaji (brez kakršnihkoli drugih težav),
-nausea, vomiting, diarrhoea, -headache, -high temperature, -lethargy, fatigue, loss of appetite
- visoka telesna temperatura,
Rare side effects (reported in less than 1 in 1000 patients): -inflammation of the pancreas (pancreatitis).
- zaspanost, utrujenost, izguba teka.
Very rare side effects (reported in less than 1 in 10,000 patients): -serious skin reactions
Redki neželeni učinki (pri manj kot 1 od 1. 000 bolnikov):
53 Cases of a condition called lactic acidosis, which is a build up of lactic acid in the body, that can cause dehydration and coma have been reported on rare occasions in patients taking NRTIs (see ” Take special care with Ziagen ” under section 2 for more information).
Pri bolnikih, ki so jemali NRTI (za več informacij glejte "Bodite posebno pozorni pri uporabi zdravila Ziagen" v poglavju 2), je v redkih primerih prišlo do bolezni, imenovane laktacidoza, to je do kopičenja mlečne kisline v telesu, kar lahko povzroči dehidracijo in komo.
These may include loss of fat from legs, arms and face, increased fat in the abdomen (belly) and other internal organs, breast enlargement and fatty lumps on the back of the neck ('buffalo hump ').
To lahko vključuje izgubo maščevja na nogah, rokah in obrazu, povečanje maščevja v abdomnu (trebuhu) in drugih notranjih organih, povečanje prsi in maščobne krpe na zadnjem delu vratu (bivolja grba).
The cause and long-term health effects of these conditions are not known at this time.
Vzrok za to in dolgoročni vplivi teh stanj na zdravje še niso znani.
Combination antiretroviral therapy may also cause raised lactic acid and sugar in the blood, hyperlipaemia (increased fats in the blood) and resistance to insulin.
Zdravljenje s kombinirano protiretrovirusno terapijo lahko povzroči tudi povišane vrednosti mlečne kisline in sladkorja v krvi, hiperlipidemijo (povišanje maščob v krvi) in odpornost na insulin
HOW TO STORE ZIAGEN
SHRANJEVANJE ZDRAVILA ZIAGEN
Do not use Ziagen after the expiry date which is stated on the package.
Zdravila ne smete jemati po datumu izteka roka uporabnosti, ki je naveden na ovojnini.
What Ziagen contains
Kaj vsebuje zdravilo Ziagen
Each Ziagen film-coated tablet contains 300 mg of the active ingredient abacavir (as sulfate).
Vsaka filmsko obložena tableta zdravila Ziagen vsebuje 300 mg zdravilne učinkovine abakavir (v obliki sulfata).
The tablet core contains microcrystalline cellulose, sodium starch glycollate, magnesium stearate and colloidal anhydrous silica.
Jedro tablete vsebuje mikrokristalno celulozo, natrijev karboksimetilškrob, magnezijev stearat in brezvodni koloidni silicijev dioksid.
The tablet coating contains triacetin, methylhydroxypropylcellulose, titanium dioxide, polysorbate 80 and iron oxide yellow.
Obloga tablete vsebuje gliceriltriacetat, hipromelozo, titanov dioksid, polisorbat 80 in rumeni železov oksid.
The film-coated, scored capsule shaped tablets are yellow and engraved with ‘ GX 623 ’ on both sides.
Rumene filmsko obložene tablete v obliki kapsule z razdelilno zarezo in oznako 'GX 623' na obeh straneh.
They are provided in blister packs containing 60 tablets.
Na voljo so v pretisnih omotih s 60 tabletami.
54 Marketing Authorisation Holder and Manufacturer (s)
56 Imetnik dovoljenja za promet z zdravilom in izdelovalec (izdelovalci)
Glaxo Operations UK Ltd (trading as Glaxo Wellcome Operations) Priory Street Ware Herts SG12 0DJ United Kingdom
Glaxo Operations UK Ltd (trading as Glaxo Wellcome Operations) Priory Street Ware Herts SG12 0DJ Velika Britanija
For any information about this medicinal product, please contact the local representative of the Marketing Authorisation Holder.
57 Za vse morebitne nadaljnje informacije o tem zdravilu se lahko obrnete na predstavništvo imetnika dovoljenja za promet z zdravilom:
Tel: + 39 (0)45 9218 111
58 Suomi/ Finland Italia GlaxoSmithKline Oy GlaxoSmithKline S. p. A.
This leaflet was last approved in {MM/ YYYY}
Navodilo je bilo odobreno
INFORMATION FOR THE USER
59 NAVODILO ZA UPORABO
Ziagen 20 mg/ ml Oral Solution abacavir
Ziagen 20 mg/ ml peroralna raztopina abakavir
It is essential you read the information on this reaction under “ Take special care with Ziagen” in section 2 of this leaflet.
Zelo pomembno je, da si podatke o tej reakciji preberete v poglavju 2 tega navodila pod naslovom "Bodite posebno pozorni pri uporabi zdravila Ziagen".
Before you take Ziagen 3.
Kaj morate vedeti, preden boste vzeli zdravilo Ziagen 3.
How to take Ziagen 4.
Kako jemati zdravilo Ziagen 4.
CD4 cells are a type of white blood cell that play an important role in maintaining a healthy immune system to help fight infection.
Odziv na
Response to treatment with Ziagen varies between patients.
60 zdravljenje z zdravilom Ziagen je od bolnika do bolnika različen.
Other frequently observed signs or symptoms include nausea, vomiting, diarrhoea, abdominal pain and severe tiredness.
Drugi, pogosteje opaženi znaki takšne reakcije so slabost, bruhanje, driska, bolečine v trebuhu in močna utrujenost.
1) you get a skin rash OR 2) you get one or more symptoms from at least TWO of the following groups
1) dobite kožni izpuščaj ALI 2) opazite enega ali več simptomov iz najmanj DVEH od spodaj naštetih skupin
- fever
- slabost ali bruhanje ali driska ali bolečine v trebuhu,
-shortness of breath, sore throat or cough -nausea or vomiting or diarrhoea or abdominal pain -severe tiredness or achiness or generally feeling ill
- močna utrujenost ali bolečine ali splošno slabo počutje.
If you have discontinued Ziagen due to a hypersensitivity reaction, YOU MUST NEVER TAKE Ziagen or any other medicine containing abacavir (i. e.
Če ste prenehali jemati zdravilo Ziagen zaradi preobčutljivostne reakcije, NIKOLI VEČ NE SMETE VZETI zdravila Ziagen ali drugega zdravila, ki vsebuje abakavir (npr.
Occasionally life-threatening hypersensitivity reactions have occurred when Ziagen was restarted in patients who reported only one of the symptoms on the Alert Card before stopping.
61 V nekaterih primerih poročajo, da so se pojavile preobčutljivosti tudi pri bolnikih, ki so znova začeli jemati zdravilo Ziagen, a so pred prenehanjem jemanja opazili samo en simptom z opozorilne kartice.
58 On very rare occasions hypersensitivity has been reported when Ziagen was restarted in patients who had no symptoms of hypersensitivity before stopping.
V izjemno redkih primerih je prišlo do preobčutljivostne reakcije pri bolnikih, ki so znova začeli jemati zdravilo Ziagen, a pred prenehanjem jemanja niso opazili nobenih simptomov preobčutljivosti.
If you are hypersensitive to Ziagen you should return all of your unused Ziagen for disposal.
Če ste preobčutljivi na zdravilo Ziagen, morate vso neporabljeno zdravilo vrniti, da se ga varno uniči.
Do not interrupt your medication without first talking to your doctor.
Ne prenehajte z jemanjem zdravila, ne da bi se o tem prej posvetovali
Treatment with Ziagen has not been shown to reduce the risk of passing HIV infection on to others by sexual contact or by blood transfer.
Znano je, da zdravljenje z zdravilom Ziagen ne zmanjša tveganja prenosa okužbe s HIV na druge ljudi s spolnim odnosom ali preko krvi.
59 Taking other medicines Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription.
Jemanje drugih zdravil Obvestite svojega zdravnika ali farmacevta, če jemljete ali ste pred kratkim jemali katerokoli zdravilo, tudi če ste ga dobili brez recepta.
This medicine contains the sweetener sorbitol (approximately 5 g in each 15 ml dose), which may have a mild laxative effect.
Pomembne informacije o nekaterih sestavinah zdravila Ziagen peroralne raztopine To zdravilo vsebuje sladilo sorbitol (približno 5 g v vsakem 15 ml odmerku), ki ima lahko blag odvajalni učinek.
Medicines containing sorbitol should not be taken if you have hereditary fructose intolerance.
Zdravil, ki vsebujejo sorbitol, ne smete jemati, če imate dedno intoleranco za fruktozo.
The usual daily dose of Ziagen in adults and adolescents over 12 years of age is 600 mg (30 ml).
Običajen dnevni odmerek pri odraslih in mladostnikih nad 12. letom starosti je 600 mg (30 ml).
This can be taken either as 300 mg (15 ml) twice a day approximately 12 hours apart or 600 mg (30 ml) once a day.
Običajen dnevni odmerek se lahko jemlje kot 300 mg (15 ml) dvakrat na dan (približno vsakih 12 ur) ali 600 mg (30 ml) enkrat na dan.
Ziagen does not have to be taken with food.
Zdravila Ziagen ni treba jemati skupaj s hrano.
60 In children three months to 12 years of age the dose given depends on the body weight of your child.
Pri otrocih od starosti treh mesecev do 12 let je odmerek odvisen od njihove telesne mase.
The recommended dose is 8 mg/ kg twice a day up to a maximum of 600 mg daily.
Priporočen odmerek je 8 mg/ kg dvakrat na dan, do skupno največ 600 mg na dan.
Use the oral dosing syringe supplied with the pack to measure your dose accurately.
Uporabite priloženo odmerno brizgo za peroralno dajanje, da točno izmerite odmerek.
Remove the bottle cap.
Odstranite pokrovček plastenke.
Push the plastic adapter into the neck of the bottle, while holding the bottle firmly.
Potisnite plastični nastavek v vrat plastenke in jo trdno držite.
Insert the syringe firmly into the adapter.
Čvrsto vstavite brizgo v nastavek.
Turn bottle upside down.
Obrnite plastenko z vrhom navzdol.
Pull out syringe plunger until the correct amount is withdrawn.
Izvlecite bat odmerne brizge dokler ne potegnete prave količine.
Turn the bottle the correct way up and remove the syringe from the adapter.
Plastenko obrnite pravilno navzgor in odstranite brizgo iz nastavka.
Replace and tighten the bottle cap.
Ponovno namestite in privijte pokrovček.
Administer the dose into the mouth by placing the tip of the syringe against the inside of the cheek.
Dajte odmerek v usta tako, da naslonite vrh brizge ob notranjost lica.
Slowly depress the plunger, allowing time to swallow.
Počasi potiskajte bat in pogoltnite odmerek.
Forceful squirting to the back of the throat may cause choking.
Močan curek v grlo lahko povzroči zadušitev.
After use the syringe must not be left in the bottle and should be washed thoroughly in clean water.
Po uporabi brizge ne smete pustiti v plastenki in jo morate temeljito umiti v čisti vodi.
It is important to take Ziagen regularly because irregular intake may increase the risk of hypersensitivity reactions.
Pomembno je, da zdravilo Ziagen jemljete redno, saj lahko neredno jemanje poveča tveganje za razvoj preobčutljivostnih reakcij.
Like all medicines, Ziagen can cause side effects although not everybody gets them.
Kot vsa zdravila ima lahko tudi zdravilo Ziagen neželene učinke, ki pa se ne pojavijo pri vseh bolnikih.
This is described under “ Take special care with Ziagen” in section 2 of this leaflet.
To je opisano pod naslovom "Bodite posebno pozorni pri uporabi zdravila Ziagen" v poglavju 2 tega navodila.
Common side effects (reported in 1 to 10 out of 100 patients):
64 Pogosti neželeni učinki (pri 1 do 10 od 100 bolnikov):
- skin rash (without any other illness)
- kožni izpuščaj (brez kakršnih koli drugih težav,
Rare side effects (reported in less than 1 in 1000 patients): -inflammation of the pancreas (pancreatitis).
Redki neželeni učinki (pri manj kot 1 od 1. 000 bolnikov):
Very rare side effects (reported in less than 1 in 10,000 patients): -serious skin reactions
Zelo redki neželeni učinki (pri manj kot 1 od 10. 000 bolnikov):
61 Cases of a condition called lactic acidosis, which is a build up of lactic acid in the body, that can cause dehydration and coma have been reported on rare occasions in patients taking NRTIs (see “ Take special care with Ziagen” in section 2 for more information).
Pri bolnikih, ki so jemali NRTI (za več informacij glejte "Bodite posebno pozorni pri uporabi zdravila Ziagen" v poglavju 2), je v redkih primerih prišlo do bolezni, imenovane laktacidoza, to je do kopičenja mlečne kisline v telesu, kar lahko povzroči dehidracijo in komo.
Combination antiretroviral therapy may also cause raised lactic acid and sugar in the blood, hyperlipaemia (increased fats in the blood) and resistance to insulin.
Zdravljenje s kombinirano protiretrovirusno terapijo lahko povzroči tudi povišane vrednosti mlečne kisline in sladkorja v krvi, hiperlipidemijo (povišanje maščob v krvi) in odpornost na insulin.
Ziagen oral solution contains 20 mg of the active ingredient abacavir (as sulfate) in each ml of the solution.
En ml Ziagen peroralne raztopine vsebuje 20 mg zdravilne učinkovine abakavir (v obliki sulfata).
Sorbitol 70% (E420), saccharin sodium, sodium citrate, citric acid anhydrous, methyl parahydroxybenzoate (E218), propyl parahydroxybenzoate (E216), propylene glycol (E1520), maltodextrin, lactic acid, glyceryl triacetate, natural and artificial strawberry and banana flavour, purified water.
Pomožne snovi: sorbitol 70% (E420), natrijev saharinat, natrijev citrat, brezvodna citronska kislina, metilparahidroksibenzoat (E218), propilparahidroksibenzoat (E216), propilenglikol (E1520), maltodekstrin, mlečna kislina, gliceriltriacetat, naravna in umetna aroma jagode in banane, prečiščena voda.
What Ziagen looks like and contents of the pack
65 Izgled zdravila Ziagen in vsebina pakiranja
Ziagen oral solution is clear to yellowish in colour with strawberry/ banana flavouring.
Ziagen peroralna raztopina je bistra, rumenkaste barve z okusom po jagodi/ banani.
The bottle contains 240 ml (20 mg abacavir/ ml) of solution.
Steklenica vsebuje 240 ml (20 mg abakavirja/ ml) raztopine.
A 10 ml oral dosing syringe and a plastic adapter for the bottle is included in the pack.
Priložena je tudi 10 ml peroralna odmerna brizga in plastični nastavek za steklenico.
62 Marketing Authorisation Holder and Manufacturer
Imetnik dovoljenja za promet z zdravilom in izdelovalec
Tel: + 39 (0)45 9218 111
67 Suomi/ Finland Italia GlaxoSmithKline Oy GlaxoSmithKline S. p. A.
or ZIMULTI
et ZIMULTI
It explains how the
pro Ta dokument je povzetek Evropskega javnega poročila o oceni zdravila (EPAR).
ra Committee for Medicinal Products for Human Use (CHMP) assessed the studies performed, to reach their recommendations on how to use the medicine.
Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil opravljene študije,, na podlagi katerih je oblikoval priporočila glede uporabe zdravila.
If you want more information on the basis
za Če potrebujete več informacij o vašem zdravstvenem stanju ali zdravljenju, preberite Navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte s svojim zdravnikom ali s farmacevtom.
ge of the CHMP recommendations, read the Scientific Discussion (also part of the EPAR).
Če želite več informacij, ki temeljijo na priporočilih CHMP, preberite znanstveno razpravo (ki je prav tako del EPAR).
What is ZIMULTI? lon ZIMULTI is a medicine containing the active substance rimonabant.
nja Kaj je zdravilo ZIMULTI?
What is ZIMULTI used for? no
ZIMULTI so zdravilo, ki vsebuje zdravilno učinkovino rimonabant.
ZIMULTI is used together with diet and exercise to treat adult patients: • who are obese (very overweight) with a body mass index (BMI) greater than or equal to 30 kg/ m², • who are overweight (with a BMI greater than or equal to 27 kg/ m²) and also have other risk factors, such as type 2 diabetes or dyslipidaemia (abnormal levels of fat in their blood).
kg/ m², ali • imajo čezmerno telesno maso (BMI večji ali enak 27 kg/ m²) in pri katerih obstajajo dodatni dejavniki tveganja, kot so na primer diabetes tipa 2 ali dislipidemija (nenormalne ravni maščobe eā
The medicine can only be obtained with a prescription. ct
Zdravilo se dobi samo na recept. av
How is ZIMULTI used? du
Kako se zdravilo ZIMULTI uporablja?
The medicine should not be used in patients who have severe problems with their liver or their kidneys. ro
ki imajo hude težave z jetri ali ledvicami.
It acts by blocking a lp
Zdravilna učinkovina v zdravilu ZIMULTI, rimonabant, je antagonist kanabinoidnih receptorjev.
specific type of receptors, the cannabinoid type 1 (CB1) receptors.
Deluje tako, da blokira specifično vrsto receptorjev, kanabinoidnih receptorjev tipa 1 (CB1), ki se nahajajo v ilo
These receptors are found in the nervous system, and they are part of the system the body uses to control food intake.
živčnem sistemu in so del sistema, ki ga telo uporablja za nadzor vnosa hrane.
The receptors are also found in adipocytes (fat tissue). ina
Receptorji se nahajajo tudi v adipocitih (maščobnem tkivu). rav
The effects of ZIMULTI were first tested in experimental models before being studied in humans.
Zd
One study looked more dic
Zdravilo ZIMULTI je bilo raziskano v štirih študijah, v katerih je sodelovalo skoraj 7000 debelih bolnikov in bolnikov s čezmerno telesno maso, katerih teža je bila na začetku študij povprečno med 94 in 104 kg.
particularly at patients with abnormal levels of blood fat, and one at patients with type 2 diabetes.
V eni študiji so podrobneje preučevali bolnike z nenormalnimi ravnmi maščob v krvi, v eni pa bolnike z diabetesom tipa 2.
Me
V študijah so primerjali učinek zdravila ZIMULTI z učinkom placeba (zdravila brez zdravilne učinkovine) na zmanjšanje telesne mase v enem do dveh let.
7 Westferry Circus, Canary Wharf, London, E14 4HB, UK Tel.
Ena študija je preučevala tudi, kako 7 Westferry Circus, Canary Wharf, London, E14 4HB, UK Tel.
©EMEA 2007 Reproduction and/ or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged.
©EMEA 2007 Reproduction and/ or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged. doseženo zmanjšanje telesne mase obdržati tekom drugega leta.
Four studies of ZIMULTI as a help to stop smoking were also carried out in over 7,000 patients,
V štirih študijah, v katerih so preučevali zdravilo ZIMULTI kot pomoč pri prenehanju kajenja, je sodelovalo preko 7000 bolnikov.
d comparing it with placebo, and measuring the effect of the medicine given for 10 weeks (one year in one
Zdravilo so primerjali s placebom in merili učinek zdravila, uporabljanega 10 tednov (eno leto v eni od študij), na prenehanje kajenja ter na ponoven začetek kajenja v naslednjem letu.
ise of the studies) on smoking cessation, and on relapses in the following year.
Kakšne koristi je zdravilo ZIMULTI izkazalo med raziskavami?
After one year, all patients who received ZIMULTI lost more weight than those who received placebo:
et Po enem letu se je pri bolnikih, ki so prejemali zdravilo ZIMULTI telesna masa zmanjšala bolj kot pri tistih, ki so prejemali placebo: povprečno so izgubili 4, 9 kg več kot s placebom, razen v študiji z
or they lost on average 4.9 kg more than placebo, except in the study in diabetic patients, where the difference in the weight loss was 3.9 kg.
m diabetičnimi bolniki, kjer je bila razlika v zmanjšanju telesne mase 3, 9 kg.
uth was difficult to estimate.
pro Študije v zvezi s prenehanjem kajenja niso pokazale konsistentnih rezultatov, učinek zdravila ZIMULTI na tem področju pa je bilo težko oceniti.
What is the risk associated with ZIMULTI?
za Kakšna tveganja so povezana z zdravilom ZIMULTI?
ra During the studies, the most common side effects with ZIMULTI (seen in more than 1 patient in 10) were nausea (feeling sick) and infections of the upper respiratory tract.
Neželeni učinki zdravila ZIMULTI, ki so bili med študijami najpogosteje opaženi (pri več kot 1 od 10 bolnikov), so navzeja (občutek slabosti) in okužbe zgornjih dihal.
ZIMULTI should not be used in patients who may be hypersensitive (allergic) to rimonabant or any of the
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila ZIMULTI, glejte Navodilo za uporabo.
ge other ingredients, or in women who are breast feeding.
nja Zdravila ZIMULTI ne smejo uporabljati osebe, ki utegnejo biti preobčutljive za (alergične na) rimonabant ali katero koli drugo sestavino zdravila ter ženske, ki dojijo.
It must also not be used in patients with ongoing major depression or who are being treated with antidepressants, since it can increase the risk of depression, including thoughts about suicide in a small minority of patients.
Zdravilo lahko poveča tveganje za depresijo, vključno s samomorilnimi mislimi pri majhnem številu bolnikov, zato se ne sme uporabljati pri bolnikih s lje trenutno potekajočo veliko depresivno motnjo ali bolnikih, ki se zdravijo z antidepresivi.
Caution should be lon used when taking ZIMULTI with some medicines, such as ketoconazole or itraconazole (anti-fungal medicines), ritonavir (used in HIV infection), or telithromycin or clarithromycin (antibiotics).
Bolniki, pri katerih se pojavi depresija, se morajo pogovoriti z zdravnikom, zdravljenje pa bo morda porebno prekiniti. vo Pri sočasnem jemanju zdravila ZIMULTI in nekaterih drugih zdravil, kot so ketokonazol ali itrakonazol (zdravili proti glivicam), ritonavir (ki se uporablja pri okužbi s HIV), telitromicin ali klaritromicin (antibiotika) je potrebna previdnost. do
The Committee for Medicinal products for Human Use (CHMP) concluded that ZIMULTI had shown its no
Odbor za zdravila za uporabo v humani medicini (CHMP) je sklenil, da je zdravilo ZIMULTI izkazalo učinkovitost pri zmanjšanju telesne mase pri debelih bolnikih in bolnikih s čezmerno telesno maso, pri eā
effectiveness in weight reduction in obese or overweight patients with associated risk factors.
Odločil je da so koristi zdravila ZIMULTI večje od z njim povezanih tveganj, kadar se uporablja kot dodatek k dieti in telesni dejavnosti pri zdravljenju debelih av
The Committee decided that ZIMULTI’ s benefits are greater than its risks when used, in addition to diet and exercise, to treat obese patients and overweight patients with risk factors such as type 2 diabetes or dyslipidaemia.
bolnikov in bolnikov s čezmerno telesno maso z dodatnimi dejavniki tveganja kot so diabetes tipa 2 ali dispidemija.